CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

219 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BBRAFV600EPredictiveSupportsSensitivity/ResponsePapillary Thyroid CarcinomaVemurafenibBrose et al., 2016
BBRAFL505HPredictiveSupportsResistanceMelanomaVemurafenibHoogstraat et al., 2015
CBRAFV600EPredictiveSupportsSensitivity/ResponseMultiple MyelomaVemurafenibSharman et al., 2014
BBRAFV600PredictiveSupportsSensitivity/ResponseMelanomaTrametinibFlaherty et al., 2012
BBRAFV600EPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabDi Nicolantonio et al., 2008
BBRAFV600EPrognosticSupportsPoor OutcomeColorectal CancerSouglakos et al., 2009
BBRAFV600EPredictiveSupportsResistanceColorectal CancerOxaliplatinSouglakos et al., 2009
BBRAFV600EPredictiveSupportsResistanceColorectal CancerIrinotecanSouglakos et al., 2009
BBRAFV600EPredictiveSupportsResistanceColorectal CancerOxaliplatin,Bevacizumab,CapecitabineTol et al., 2009
BBRAFMutationPredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
CBRAFD594GPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,IrinotecanDe Roock et al., 2010
BBRAFV600EPrognosticSupportsPoor OutcomePapillary Thyroid CarcinomaKim et al., 2012
CBRAFAmplificationPredictiveSupportsResistanceColorectal CancerDabrafenib,PanitumumabAhronian et al., 2015
BBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibRutkowski et al., 2015
BBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibUgurel et al., 2015
CBRAFV600EPredictiveSupportsSensitivity/ResponseChildhood Pilocytic AstrocytomaVemurafenibdel Bufalo et al., 2014
CBRAFV600EPredictiveSupportsSensitivity/ResponseOvarian Serous CarcinomaVemurafenibCombe et al., 2015
CBRAFV600EPredictiveSupportsResistanceColorectal CancerPanitumumabDe Roock et al., 2010
BBRAFV600KPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibUgurel et al., 2015
BBRAFV600KPredictiveSupportsSensitivity/ResponseSkin MelanomaDabrafenib,TrametinibRobert et al., 2015
CBRAFD594GPredictiveSupportsResistanceColorectal CancerCetuximab,IrinotecanHsu et al., 2016
DBRAFV600DPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibTsai et al., 2008
DBRAFV600E AND PIK3R2 N561DPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
CBRAFL597QPredictiveSupportsSensitivity/ResponseSkin MelanomaTrametinibBowyer et al., 2014
CBRAFV600EPredictiveSupportsSensitivity/ResponseCholangiocarcinomaDabrafenib,TrametinibKocsis et al., 2017
CBRAFV600EPredictiveSupportsSensitivity/ResponseIntrahepatic CholangiocarcinomaTrametinib,DabrafenibLavingia et al., 2016
CBRAFV600EPredictiveSupportsSensitivity/ResponseIntrahepatic CholangiocarcinomaDabrafenib,TrametinibLoaiza-Bonilla et al., 2014
CBRAFV600EPredictiveSupportsSensitivity/ResponseCholangiocarcinomaVemurafenib,Irinotecan,PanitumumabSilkin et al., 2016
BBRAFV600EPredictiveSupportsSensitivity/ResponseOvarian CancerVemurafenibHainsworth et al., 2018
CBRAFV600EPredictiveSupportsSensitivity/ResponseAnaplastic Thyroid CarcinomaVemurafenib,PertuzumabHainsworth et al., 2018
CBRAFV600EPredictiveSupportsSensitivity/ResponseLaryngeal Squamous Cell CarcinomaVemurafenibHainsworth et al., 2018
DBRAFD594GPredictiveSupportsSensitivity/ResponseSkin MelanomaSorafenibSmalley et al., 2009
DBRAFD594GPredictiveSupportsResistanceSkin MelanomaU0126Smalley et al., 2009
DBRAFG469EPredictiveSupportsSensitivity/ResponseSkin MelanomaSorafenibSmalley et al., 2009
DBRAFG469EPredictiveSupportsResistanceSkin MelanomaU0126Smalley et al., 2009
BBRAFV600EPredictiveSupportsSensitivity/ResponseAnaplastic Thyroid CarcinomaVemurafenibHyman et al., 2015
BBRAFV600PredictiveSupportsSensitivity/ResponseColorectal CancerCetuximab,Alpelisib,Encorafenibvan Geel et al., 2017
BBRAFV600EPredictiveDoes Not SupportSensitivity/ResponseColorectal AdenocarcinomaPanitumumab,TrametinibCorcoran et al., 2018
BBRAFMutationPrognosticSupportsPoor OutcomeColorectal CancerSouglakos et al., 2009
BBRAFMutationPredictiveSupportsResistanceColorectal CancerOxaliplatinSouglakos et al., 2009
BBRAFMutationPredictiveSupportsResistanceColorectal CancerIrinotecanSouglakos et al., 2009
BBRAFMutationPredictiveSupportsResistanceColorectal CancerBevacizumabSouglakos et al., 2009
BBRAFMutationPredictiveSupportsResistanceColorectal CancerCetuximabSouglakos et al., 2009
BBRAFMutationPrognosticSupportsPoor OutcomeColorectal CancerSouglakos et al., 2009
BBRAFintron 10 rearrangementPredictiveSupportsResistanceMelanomaVemurafenib,DabrafenibShi et al., 2014
BBRAFintron 9 rearrangementPredictiveSupportsResistanceMelanomaVemurafenib,DabrafenibShi et al., 2014
BBRAFD594KPredictiveSupportsResistanceColorectal CancerIrinotecanSouglakos et al., 2009
BBRAFD594KPredictiveSupportsResistanceColorectal CancerOxaliplatinSouglakos et al., 2009
BBRAFV600KPredictiveSupportsSensitivity/ResponseMelanomaTrametinib,DabrafenibLong et al., 2014
BBRAFV600PredictiveSupportsSensitivity/ResponseMelanomaVemurafenib,CobimetinibRibas et al., 2014
Page 3 of 5
PreviousNext